EVPM ICSR(s)		Individual Case Safety Report Form					EudraVigilance	
Genera	al Information							
EudraVigilance Local Report Number		EU-E	C-10008557015					
Sender Type		Regul	latory authority					
Sender's Organisation		EEA I	Regulator					
Type of Report		Spont	Spontaneous					
Primary source country		Europ	European Economic Area					
Reporter's qualification		Healtl	Healthcare Professional					
Case serious?		Yes	Yes					
Patient	t							
Age Group			Age Group (as per reporter)				Sex	
12-17 Years			Adolescent			Male		
Reaction	on / Event							
MedDRA LLT		Duration		Outcome			Seriousness <sup>1</sup>	
Cardiac arrest		0.0 Days		Fatal			death., hospital., other	
Pulmonary embolism		0.0 Days		Fatal			death., hospital., other	
Drug Ir	nformation							
Role <sup>2</sup>	Drug		Duration	Dose	Units in In	nterval	Action taken	
COMIRNATY COVID-19 MRNA VACCINE S (NUCLEOSIDE MODIFIED) CONCENTRA DISPERSION FOR INJECTION - TOZINAN		RATE FOR		0.3 mL	Tota	I	Not applicable	
С	- METHYLPREDNISOLONE			16.0 mg	Days	3	Not applicable	
С	- CICLOSPORIN			50.0 mg	Hour	S	Not applicable	
С	- AZITHROMYCIN			500.0 mg	Week	s	Not applicable	
Drug Ir	nformation (cont.)							
Info <sup>3</sup>	Drug		Indication		Pharm. For	m	Route of Admin.	
	COMIRNATY COVID-19 MRNA VACCIN (NUCLEOSIDE MODIFIED) CONCENTION DISPERSION FOR INJECTION - TOZIN	RATE FOR	Active immuniza	ation			Intramuscular use	
	- METHYLPREDNISOLONE		N/A				Oral use	
	- CICLOSPORIN		N/A				Oral use	
- AZITHROMYCIN			N/A				Oral use	
Recha	llenge matrix table							
Reaction/Event (MedDRA LLT)		Drug				Rechallenge? / Reaction recurred?		
Cardiac arrest		COMIRNATY COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) CONCENTRATE FOR DISPERSION FOR				no - n/a		

Rechallenge matrix table								
Reaction/Event (MedDRA LLT)	Drug	Rechallenge? / Reaction recurred?						
Cardiac arrest	COMIRNATY COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) CONCENTRATE FOR DISPERSION FOR INJECTION - TOZINAMERAN	no - n/a						
Pulmonary embolism	COMIRNATY COVID-19 MRNA VACCINE (NUCLEOSIDE MODIFIED) CONCENTRATE FOR DISPERSION FOR INJECTION - TOZINAMERAN	no - n/a						

Seriousness: death=results in death; life threat.=life threatening; hospital.=requires hospitalization/prolongation of hospitalization; disability=results in disability/incapacity; congen.=congenital anomaly/birth defect; other=other medically important information; (blank)=non-serious

 $<sup>2 \</sup>quad \text{Drug role: } \textbf{S} \!\!=\!\! \text{suspect; } \textbf{C} \!\!=\!\! \text{concomitant; } \textbf{I} \!\!=\!\! \text{interacting; } \textbf{N} \!\!=\!\! \text{not administered}$ 

Additional Information on Drug: 1=Counterfeit; 2= Overdose; 3=Drug taken by the father; 4=Drug taken beyond expiry date; 5=Batch and lot tested and found within specifications; 6=Batch and lot tested and found not within specifications; 7=Medication error; 8=Misuse; 9=Abuse; 10=Occupational exposure; 11=Off label use; (blank) = no additional information